Oxford Nanopore Technologies plc (LON:ONT)
London · Delayed Price · Currency is GBP · Price in GBX 122.70
-2.00 (-1.60%)
At close: Mar 18, 2026
LON:ONT Revenue
In the year 2025, Oxford Nanopore Technologies had annual revenue of 223.90M GBP with 22.22% growth. Oxford Nanopore Technologies had revenue of 118.30M in the half year ending December 31, 2025, with 41.40% growth.
Revenue
223.90M
Revenue Growth
+22.22%
P/S Ratio
5.30
Revenue / Employee
167.72K
Employees
1,335
Market Cap
1.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 223.90M | 40.71M | 22.22% |
| Dec 31, 2024 | 183.19M | 13.52M | 7.97% |
| Dec 31, 2023 | 169.67M | -28.94M | -14.57% |
| Dec 31, 2022 | 198.60M | 64.94M | 48.59% |
| Dec 31, 2021 | 133.66M | 19.80M | 17.39% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genus | 672.00M |
| Oxford Biomedica | 151.21M |
| hVIVO | 54.47M |
| Bioventix | 13.12M |
| Scancell Holdings | 4.71M |
| PureTech Health | 4.66M |
| 4basebio | 1.78M |
| Ondine Biomedical | 1.18M |
Oxford Nanopore Technologies News
- 1 day ago - Oxford Nanopore and A.D.A.M. Innovations Announce International Collaboration to Accelerate Advanced Genomic Medicine in Japan - Business Wire
- 7 days ago - Oxford Nanopore Technologies PLC at Barclays Global Healthcare Conference Transcript - GuruFocus
- 7 days ago - Oxford Nanopore Technologies plc (ONTTF) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 8 days ago - ViruSure Launches First GMP-Validated Viral Safety Test Based on Oxford Nanopore Sequencing - Business Wire
- 16 days ago - Oxford Nanopore Technologies plc (ONTTF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Full Year 2025 Oxford Nanopore Technologies PLC Earnings Presentation Transcript - GuruFocus
- 19 days ago - Oxford Nanopore Technologies PLC (LSE:ONT) Q4 2025 Earnings Report Preview: What To Look For - GuruFocus
- 2 months ago - Oxford Nanopore Technologies plc (ONTTF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha